Clinical trial
High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1…
NCT00381953 · Foundation for Liver Research, Other · Completed
Key facts
| NCT number | NCT00381953 |
|---|---|
| Title | High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV |
| Official title | A Comparative Study of High-dose Interferon Alfa-2a and Pegylated Interferon Alfa-2a for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV |
| Lead sponsor | Foundation for Liver Research, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Drug |
| Interventions | Peginterferon alfa-2a, Interferon alfa-2a, Ribavirin |
| Enrollment | 33 |
| Start date | Feb 1, 2003 |
| Primary completion | Apr 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Sep 28, 2006 |
| Last update posted | Sep 1, 2021 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: